was performed, with CBF held constant, under baseline and during dobutamine, CaCl 2 , or amrinone at doses increasing SS by ϳ50% (10 g/min, 15 mg/min, and 300 g/min ic, respectively). ACh-induced responses during dobutamine were also assessed following treatment with the NO synthase inhibitor N G -nitro-L-arginine methyl ester (L-NAME; 300 g/ min ic for 15 min). The effects of sodium nitroprusside (SNP; 80 g/min ic), an exogenous NO donor, bradykinin (2.5 g/ min ic), a nonmuscarinic releaser of endothelial NO, and bilateral vagal stimulation (before and after L-NAME) were evaluated during dobutamine. ACh had no effect on SS under baseline or during CaCl 2 , but it decreased SS during dobutamine or amrinone (Ϫ23 Ϯ 4% and Ϫ30 Ϯ 5%, respectively). Vagal stimulation also reduced SS during dobutamine. L-NAME did not alter the ACh-or vagal-induced decreases in SS during dobutamine. Neither SNP nor bradykinin affected SS during dobutamine. In conclusion, ACh and vagal stimulation have a negative inotropic effect during stimulation of the ␤-adrenergic receptors that is independent of NO. The persistence of this effect during amrinone suggests that a mechanism downstream from adenylate cyclase is involved. coronary circulation; endothelium; bradykinin; sodium nitroprusside; amrinone; N G -nitro-L-arginine methyl ester; canine hearts SYMPATHETIC AND PARASYMPATHETIC divisions of the autonomic nervous system play antagonistic roles in control of cardiac activity (29). Stimulation of the sympathetic nervous system increases heart rate (sinoatrial node automaticity), atrioventricular conduction, and ventricular contractility, and stimulation of the parasympathetic nervous system reduces heart rate and atrioventricular conduction. While stimulation of the parasympathetic (vagus) nervous system has minimal effects on ventricular contractility under basal conditions, it reduces contractility during sympathetic stimulation or administration of ␤-adrenergic agonists. This adrenergic-cholinergic interaction was first suggested in the mid-1960s by Hollenberg et al. (21), who observed that intracoronary infusions of the parasympathetic neurotransmitter ACh in dogs had minimal effects on myocardial contractility except during sympathetic stimulation or infusions of norepinephrine, when they produced severe cardiac depression. This phenomenon has subsequently been confirmed in various animal models (19, 20, 26, 38) and in human subjects (25).
SYMPATHETIC AND PARASYMPATHETIC divisions of the autonomic nervous system play antagonistic roles in control of cardiac activity (29) . Stimulation of the sympathetic nervous system increases heart rate (sinoatrial node automaticity), atrioventricular conduction, and ventricular contractility, and stimulation of the parasympathetic nervous system reduces heart rate and atrioventricular conduction. While stimulation of the parasympathetic (vagus) nervous system has minimal effects on ventricular contractility under basal conditions, it reduces contractility during sympathetic stimulation or administration of ␤-adrenergic agonists. This adrenergic-cholinergic interaction was first suggested in the mid-1960s by Hollenberg et al. (21) , who observed that intracoronary infusions of the parasympathetic neurotransmitter ACh in dogs had minimal effects on myocardial contractility except during sympathetic stimulation or infusions of norepinephrine, when they produced severe cardiac depression. This phenomenon has subsequently been confirmed in various animal models (19, 20, 26, 38) and in human subjects (25) .
Traditionally, the ACh-induced reductions in myocardial contractility have been attributed to stimulation of muscarinic receptors on the cardiomyocytes, leading to a G protein-mediated decrease in adenylate cyclase activity and a resultant fall in cAMP levels (11, 13, 20) . However, the ability of ACh to release nitric oxide (NO) from the coronary vascular endothelium (4) and in vitro studies demonstrating NO-induced cardiac depression (5) have provided a theoretical basis for a role for the NO-cGMP pathway in the negative inotropic effects of ACh. According to this hypothesis, AChinduced stimulation of the muscarinic receptors causes release of NO, which diffuses to the underlying myocytes where it stimulates production of cGMP, whose negative inotropic action offsets the effect of cAMP. Despite intensive investigation, the role of the NOcGMP pathway in the ACh-induced reductions in myocardial contractility remains unresolved (10, 12, 16, 18, 19, 30, 31, 37, 39) .
The present study employed a canine model, permitting tight control of hemodynamic conditions, to investigate ACh-induced effects on myocardial contractility in vivo. In our initial studies, we wanted to identify the conditions necessary for these effects. As anticipated, ACh had a prominent negative inotropic effect only when it was infused in the presence of the ␤-adrenergic receptor agonist dobutamine. We then evaluated the role of NO in this effect by attempting to attenuate the effect with the NO synthase inhibitor N G -nitro-L-arginine methyl ester (L-NAME) and to mimic it with bradykinin, a nonmuscarinic releaser of NO from the coronary vascular endothelium (34) , or sodium nitroprusside (SNP), an exogenous NO donor (32) . We then assessed the effect of ACh on the increases in myocardial contractility caused by the cAMP-phosphodiesterase inhibitor amrinone (7) . The latter studies were performed to gain insight as to where in the ␤-adrenergic receptor-cAMP pathway ACh was producing an inhibitory influence on myocardial contractility. Finally, we evaluated the role of NO in physiological modulation of myocardial contractility by ACh. The ability of vagal stimulation to attenuate the myocardial contractile response to dobutamine was determined before and after L-NAME.
METHODS

Canine Preparation
The study was conducted in compliance with the Institutional Animal Research Committee. The studies were performed on 34 conditioned, heartworm-free mongrel dogs of either sex (20-30 kg) . Anesthesia was induced with a bolus intravenous injection of thiopental sodium (15 mg/kg) and maintained by continuous intravenous infusion of fentanyl and midazolam at rates of 12 g ⅐ kg Ϫ1 ⅐ h Ϫ1 and 0.6 mg ⅐ kg Ϫ1 ⅐ h Ϫ1 , respectively. In series 1 (n ϭ 29 dogs), supplemental intravenous bolus injections of fentanyl were given as necessary to maintain a stable heart rate at ϳ130 beats/min. In series 2 (n ϭ 5 dogs), the heart was paced. After the trachea was intubated and a left thoracotomy was made in the fourth intercostal space, the lungs were mechanically ventilated (Air Shields; Hatboro, PA) with the volume and rate of the ventilator and the fractional inspired O 2 concentration adjusted to maintain arterial PO 2 , PCO 2 , and pH at 272 Ϯ 27 mmHg, 38 Ϯ 1 mmHg, and 7.39 Ϯ 0.01, respectively. Blood gases and pH of arterial blood samples were measured electrometrically (model 413, Instrumentation Laboratories; Lexington, MA). Body temperature was maintained at 38°C with a heating pad. Lactated Ringer solution was administered continuously at a rate of 5 ml ⅐ kg Ϫ1 ⅐ h
Ϫ1
intravenously to compensate for fluid losses. Hematocrit averaged 33 Ϯ 1%. Polyethylene cannulas were inserted into the thoracic aorta via the right carotid artery for measuring arterial blood pressure, the left atrium for measuring left atrial pressure, the right femoral artery for collecting samples of arterial blood for gas analysis, and the right femoral vein for administration of heparin sodium (400 U/kg with supplementation) for anticoagulation and of supplementary anesthetic.
A micromanometer-tip pressure transducer (Millar Instruments; Houston, TX) was inserted into the left ventricle via the left atrium and mitral valve to measure left ventricular pressure. The maximum rate of rise of left ventricular systolic pressure (dP/dt max ) was obtained from the left ventricular pressure pulse with an electronic differentiator. The left ventricular pressure signal was used to drive a cardiotachometer. Arterial pressure, left atrial pressure, and coronary perfusion pressure were measured with Statham pressures transducers (model P23ID, Gould; Cleveland, OH). A continuous record of blood pressures, left ventricular dP/dt max , heart rate, coronary blood flow, and segmental length were obtained on a physiological recorder (model 2800S, Gould).
The left anterior descending (LAD) coronary artery was isolated ϳ2 cm from its origin for cannulation. A thin-wall stainless steel cannula (2.5-mm inside diameter) was introduced into the isolated segment of the LAD, so that the artery could be perfused selectively via an extracorporeal system (6) . Briefly, this system consisted of a reservoir (pressurized with compressed gas) that was supplied by a peristaltic pump with blood from the left femoral artery. The tubing connecting the reservoir to the LAD was equipped with the following: 1) a heat exchanger to maintain temperature of the arterial blood perfusate at 38°C, 2) an ultrasonic, transient-time flow transducer (Transonic Systems; Ithaca, NY) to measure coronary blood flow, 3) ports for collecting blood samples and for infusing drugs, and 4) a mixing chamber for drugs administered into the perfusion tubing. Coronary perfusion pressure was measured through a small-diameter tube positioned at the orifice of the perfusion cannula. To avoid hypovolemia in the experimental animal, lactated Ringer solution was infused intravenously during priming of the perfusion system.
At the termination of each experiment, Evans blue dye was injected into the LAD to identify its perfusion territory. After the heart was stopped with KCl, it was removed and trimmed. The dyed tissue was excised and weighed so that coronary blood flow could be expressed on a per-100-g basis. The LAD perfusion territory weighed 33 Ϯ 1 g.
Experimental Measurements
Myocardial segment shortening. Changes in myocardial contractility in the LAD perfusion field were evaluated from measurements of segmental shortening (SS) obtained using the ultrasonic crystal technique (6) . A pair of crystals was implanted to a subendocardial depth in the LAD perfusion field. This location was verified by segmental lengthening during the brief (Ͻ2 min) period of flow stoppage required for cannulation of the LAD. The crystals were oriented so that they were parallel with the anticipated direction of myocardial fibers in the left ventricular subendocardium (36) . Changes in distance between the crystals were recorded from measurements of the ultrasonic transit time between the crystals (Triton Technology; San Diego, CA). The end-diastolic length (EDL) and end-systolic length (ESL) were identified by the beginning of the rapid increase in left ventricular pressure just before isovolumetric contraction and ϪdP/ dt min , respectively. SS (in percent) was calculated from the formula SS ϭ [(EDL Ϫ ESL)/EDL] ϫ 100.
Experimental Protocols
Series 1: unpaced hearts. At least 45 min was allowed for recovery from surgical preparation before experimental runs were initiated. A total of 1-5 experimental trials were performed in each animal. Values for SS and coronary hemodynamic parameters were obtained 2-3 min after initiating a drug infusion (at a time that steady-state conditions prevailed). At least 15 min was allowed for recovery after each experimental trial. In our initial studies, the changes in SS were evaluated during intracoronary infusions of ACh alone (n ϭ 10; 20 g/min) and during CaCl 2 (n ϭ 6) or dobutamine (n ϭ 10) administered at 15 mg/min and 10 g/min ic, respectively. We chose our dose for ACh because it was the highest that could be used without causing aortic hypotension secondary to recirculation into the systemic circulation (6) , and those for dobutamine and CaCl 2 because they caused the maximal increases in SS possible without systemic hemodynamic effects (7-9). Baseline measurements were initially obtained with coronary perfusion pressure set at 80 mmHg. Coronary perfusion pressure was held constant during the intracoronary infusions of dobutamine and CaCl 2 , which permitted the normal coronary hyperemia accompanying augmented contractile activity. Coronary blood flow was held constant during the intracoronary infusions of ACh (both in the absence and presence of dobutamine and CaCl 2 ) to avoid masking a potential negative inotropic effect by Gregg's phenomenon (15) and to avoid diluting the inotropic agents in the coronary blood supply. This was accomplished by reducing coronary perfusion pressure manually, as necessary to offset the vasodilating effect of ACh. An analogous protocol was used in subsequent studies in series 1. The effect of ACh on SS was evaluated during dobutamine after treatment with L-NAME (n ϭ 6; 300 g/min ic, for 15 min), and the effects of bradykinin (n ϭ 7; 2.5 g/min ic) and SNP (n ϭ 9; 80 g/min ic) were assessed during dobutamine. Additional studies were conducted to clarify the effects of bradykinin alone (n ϭ 7) on SS. Our dose for L-NAME was adopted from previous studies (8), which showed that it produced a 70-80% attenuation of the ACh-induced increases in coronary blood flow without effects on systemic circulatory variables or on the increases in coronary blood flow caused by SNP. The doses for SNP and bradykinin were selected on the basis of preliminary studies indicating that they caused a decrease in coronary perfusion pressure, i.e., vascular relaxation, which was comparable to that during ACh. In our final studies in series 1, we assessed the effect of ACh during amrinone at 300 g/min ic, which was sufficient to increase SS to an extent similar to that caused by dobutamine. All drugs infused into the LAD perfusion line were dissolved in isotonic saline to achieve concentrations that permitted intracoronary infusions at 1.0 ml/min. Preliminary studies demonstrated that infusions of the saline vehicle at this low rate had no effect on SS or coronary blood flow.
Series 2: paced hearts. Series 2 dogs were prepared as described above under series 1 with several additions. The cervical vagus nerves were identified through a midline incision, double ligated, and transected between the two ligatures. Shielded electrodes were applied to the cardiac segments of each vagus nerve. The electrodes were connected to an electronic stimulator with stimulator isolation units (Grass Instruments; Quincy, MA). Our plan was to stimulate the vagus nerves at frequencies that would alter heart rate and, in turn, ventricular function in animals with intact atrioventricular (AV) conduction. Therefore, in each dog in series 2, we produced a complete AV block and paced the heart. The technique described by Steiner and Kovalik (35) was used to produce the AV block. In brief, a right thoracotomy was performed and Ͻ1.0 ml of 40% formaldehyde was injected into the AV junction. After a complete AV block was confirmed with the use of the electrocardium, the right thoracotomy was closed, the dog was turned on its opposite side, and a left thoracotomy was performed. The heart was then instrumented as described above. Heart rate was maintained at 100 beats/min by pacing the ventricles through a bipolar electrode attached to the anterior surface of the right ventricle free wall.
The paced hearts were used in experiments to evaluate the ability of L-NAME to modify the vagal-and bradykinininduced changes in myocardial contractility (and coronary perfusion pressure) during intracoronary dobutamine. The basic experimental design and the drug doses used in these studies were identical to those described above under series 1. In accordance with the previous studies of Hare et al. (19) and Henning et al. (20) , bilateral vagal stimulation was applied at 2.5 and 5.0 Hz in random order for 90 s by using a pulse duration of 0.5 ms and a supramaximal voltage of 15 V. After effects of vagal stimulation and bradykinin infusion were assessed in the absence of L-NAME, L-NAME was infused, and the effects of vagal stimulation and bradykinin reevaluated. A 10-min recovery period was allowed between the vagal stimulation and bradykinin experimental trials. The order of the vagal stimulations and the bradykinin infusions was randomized.
Statistical analysis was performed using the Student's t-test for paired and unpaired samples, as appropriate, and an analysis of variance in combination with the StudentNewman-Keuls test (14) . P Ͻ 0.05 was considered significant throughout the study.
RESULTS
Series 1: unpaced hearts. ACh had no effect on SS under baseline conditions or during CaCl 2 , but it reduced SS during dobutamine sufficiently to return SS to the control level (Table 1) . ACh also caused pronounced decreases in coronary perfusion pressure under all conditions, which, under constant-flow conditions, reflected proportional reductions in coronary vascular resistance (Table 1) . Figure 1 presents an original tracing demonstrating the ability of ACh to reverse the positive inotropic effect of dobutamine. At trace A, the intracoronary infusion of dobutamine was initiated, and at trace B the infusion of ACh was added. Dobutamine increased SS markedly, accompanied by a modest increase in coronary blood flow. The additional intracoronary infusion of ACh reversed the effect of dobutamine on SS, and it caused a pronounced reduction in coronary perfusion pressure. The stability of systemic hemody- Values are means Ϯ SE; n ϭ 10 dogs for ACh alone, n ϭ 6 dogs for ACh during CaCl 2 , n ϭ 10 dogs for ACh during pre-L-NAME, and n ϭ 6 dogs post-L-NAME. L-NAME, N G -nitro-L-arginine methyl ester. SS, segmental shortening; CPP, coronary perfusion pressure; CBF, coronary blood flow. * P Ͻ 0.05, control; † P Ͻ 0.05, CaCl 2 or dobutamine; and ‡ P Ͻ 0.05, pre L-NAME. namic parameters and the parallelism between the changes in LV dP/dt max and SS during the intracoronary infusions of drugs were noteworthy. This pattern of response was observed consistently throughout the study (Table 2) . L-NAME had no effect on the ACh-induced decreases in SS in dobutamine-stimulated myocardium, but it blunted the accompanying decreases in coronary perfusion pressure (Table 1 and Fig. 2 ). Neither bradykinin alone, bradykinin during dobutamine, nor SNP during dobutamine affected SS, although they caused pronounced decreases in coronary perfusion pressure (Table 3 ). Figure 3 shows an original tracing (obtained from same dog as that in Fig. 1 ) demonstrating that bradykinin, in contrast to ACh, did not alter SS in dobutamine-stimulated myocardium, although it caused a comparable decrease in coronary perfusion pressure (Table 3) .
ACh had similar effects during amrinone as it did during dobutamine; it completely negated the positive inotropic effect of amrinone, while it reduced markedly coronary perfusion pressure (Table 3) .
Series 2: paced hearts. Cardiac effects of vagal stimulation during dobutamine in series 2 were comparable to those of ACh in series 1 ( Table 1 vs. Table 4 ; Fig. 2 ). Vagal stimulation caused reductions in both SS and coronary perfusion pressure; while the reductions in SS were unaffected by L-NAME, those in coronary perfusion pressure were attenuated. Vagal stimulation had no effect on systemic hemodynamic parameters (Table 4) . As demonstrated in series 1, bradykinin had no effect on SS during dobutamine, and it caused decreases in coronary perfusion pressure ( Table 5 ). The lack of effect of bradykinin on SS persisted after L-NAME, whereas the decreases in perfusion pressure were blunted. The values for systemic hemodynamic parameters during the bradykinin infusions were similar to those presented in Table 4 for vagal stimulation. Values are means Ϯ SE; n ϭ 5 for bradykinin alone, n ϭ 7 for bradykinin during dobutamine, n ϭ 9 for SNP during dobutamine, and n ϭ 7 for ACh during amrinone. SNP, sodium nitroprusside. P Ͻ 0.05, * control and † dobutamine or amrinone. 
DISCUSSION
Critique of Methods
We have used the model of selective LAD perfusion in many studies to evaluate the direct coronary and myocardial effects of drugs and physiological factors (6) (7) (8) (9) 17) . Critical to the present study was that this model preserves receptor-mediated release of NO from the coronary vascular endothelium. Although this could not be verified by direct measurements, the observed pronounced decreases in coronary perfusion pressure during the intracoronary infusions of ACh and bradykinin and stimulations of the vagus nerves, combined with the ability of the L-NAME to significantly inhibit them, provided indirect evidence. The comparable reductions in coronary perfusion pressure by ACh, bradykinin, and SNP (Tables 1 and 2 ) suggested that these agents caused similar increases in the level of NO within the myocardium.
The ability of changes in SS to reflect changes in myocardial contractility is limited by variations in heart rate and in the loading conditions of the heart (2). The constant values for heart rate and in indices of afterload (arterial pressure) and preload (left atrial pressure) during the selective intracoronary infusions of drugs and the vagal stimulations suggested that this limitation was not a factor in the present study. The use of such infusions ensured that recovery times were short. This permitted the evaluation of multiple experimental conditions in the same preparation, which facilitated the intertreatment comparisons.
Infusion of crystalloid during priming of the extracorporeal perfusion system produced modest reductions in hematocrit. The animals were ventilated with room air enriched with oxygen to increase arterial PO 2 and thus minimize the concomitant decreases in arterial oxygen content.
Effects of ACh on Myocardial Contractility
The main findings from the present study were as follows. First, both ACh and vagal stimulation caused reductions in SS during inotropic stimulation with the ␤-adrenergic agonist dobutamine, which was not attenuated by the NO synthase (NOS) inhibitor L-NAME or mimicked by either bradykinin (a nonmuscarinic releaser of NO from the coronary vascular endothelium) or SNP (an exogenous NO donor). Second, ACh also reduced SS during inotropic stimulation with the cAMP-phosphodiesterase inhibitor amrinone.
It is well recognized that the sympathetic and parasympathetic divisions of the autonomic nervous system exert antagonistic influences on various aspects of cardiac performance (29) . However, these opposing effects are not algebraically related; complicated interactions are evident. The ability of sympathetic stimulation to enhance the negative inotropic effects of vagal stimulation, termed "accentuated antagonism" (26) , has been appreciated for many years (21) . In the present study, intracoronary infusions of ACh and the ␤-adrenergic receptor agonist dobutamine were used to simulate this effect.
Accentuated antagonism was demonstrated dramatically in the current study; intracoronary infusions of ACh had no effect on contractility in unstimulated myocardium, whereas they inhibited contractility markedly in dobutamine-stimulated myocardium. The failure of ACh to affect myocardial contractility during inotropic stimulation with CaCl 2 ruled out the possibility that the findings during dobutamine were simply the result of an augmented baseline contractile activity. The subcellular pathway underlying the ␤-adrenergic-induced augmentation in myocardial contractility has been described in detail. It involves stimulation of adenylate cyclase, which causes an increased conversion of ATP to cAMP within the cardiomyocytes, leading to phosphorylation of the voltage-sensitive Ca 2ϩ channels and Ca 2ϩ influx. It is known that muscarinic receptors are coupled to adenylate cyclase by an inhibitory G protein (11, 13 ). An activation of this G protein has been longed considered integral to the ACh-induced reductions in myocardial contractility during activation of the ␤-adrenergic receptors (20) . It has been suggested that an inhibition of norepinephrine release from the sympathetic nerve terminals may also contribute (27) .
Previous studies (10, 12, 16, 18, 19, 30, 31, 37, 39) , primarily performed in vitro, have considered a role for an additional mechanism, i.e., the NO-cGMP pathway, in cholinergic inhibition of myocardial contractility. The results of these studies have been inconsistent. For example, on behalf of a role for this pathway, George et al. (12) showed that ACh caused increases in cGMP levels that were associated with negative inotropic effects in isolated unstimulated rat hearts. Watanabe and Besch (39) showed that ACh-induced increases in cGMP levels in guinea pig ventricles produced negative inotropic effects when they were combined with a cAMP-increasing drug, such as isoproterenol. Han et al. (18) recently reported that targeted disruption of the constitutive endothelial NOS gene completely abolished the decreases in calcium channel current and contractile amplitude caused by the muscarinic agonist carbachol in isoproterenol-stimulated mouse ventricular myocytes. On the other hand, Groschner et al. (16) reported that ACh reduced contractility in isolated guinea pig atria, although it had no effect on cGMP concentration. Endo and Shimizu (10) demonstrated a failure of 8-bromo-cGMP to mimic the antagonistic action of carbachol on contractility of isolated canine right ventricular myocardium exposed to isoproterenol. MacDonell et al. (30) found that ACh and carbachol both inhibited the positive inotropic effect of isoproterenol in rat ventricular myocytes, while SNP had no effect, even though the three agents caused similar increases in cGMP concentration. Méry et al. (31) showed that neither L-arginine (the substrate of NO) nor two NOS inhibitors affected the ability of ACh to reduce contractility of isolated frog ventricular fibers stimulated with isoproterenol. Finally, in apparent direct contradiction to the work of Han et al. (18) alluded to above, Vandecasteele et al. (37) demonstrated that papillary muscles obtained from genetically engineered mice without endothelial constitutive NOS retained normal negative inotropic responses to carbachol during ␤-adrenergic stimulation. These widely divergent findings are likely attributable to the peculiarities of the various in vitro models utilized, and they point out the difficulty in extrapolating findings from such models to the intact heart in vivo.
Our findings during vagal stimulation are in apparent conflict with those of Hare et al. (19) , which demonstrated that NOS inhibition blunted the reduction in myocardial contractility caused by vagal stimulation during an intracoronary infusion of dobutamine in anesthetized dogs, thus implying a role for the NOcGMP pathway. The cause for this discrepancy is uncertain, but it may be related to methodological differences, including the use of a different anesthetic (␣-chloralose) and a higher heart pacing rate (170-180 beats/min) by Hare et al. (19) . Another factor may be that Hare et al. (19) allowed coronary blood flow to vary naturally. The increases in coronary blood flow during vagal stimulation in the study of Hare et al. (19) would have diluted the dobutamine infused into the coronary artery, thus potentially contributing to the observed reductions in contractility. This factor would have been attenuated after NOS inhibition. It is possible that Hare et al. (19) mistook an accentuated dobutamineinduced positive inotropic effect following NOS inhibition for a blunted negative inotropic effect via the NO-cGMP pathway. Because we held coronary blood flow constant during the vagal stimulations, varying coronary arterial levels for dobutamine did not complicate our findings.
An additional new finding from the present study was that ACh had a negative inotropic effect during administration of the cAMP phosphodiesterase inhibitor amrinone. This finding implies that ACh interferes with a cAMP-related mechanism downstream from adenylate cyclase. Previous studies conducted in in vitro cardiac models suggest possible targets for this effect. ACh may be stimulating cAMP phosphodiesterase (thus directly offsetting the influence of amrinone) (24) , and/or it may be increasing phosphatase activity, which would attenuate phosphorylation of phospholamban (1, 28) . Both these mechanisms would theoretically result in a return of Ca 2ϩ influx and myocardial contractility towards preamrinone levels.
Like ACh (Table 1) and SNP in our previous study (6) , bradykinin, when infused directly into the coronary artery, had no effect on contractility in unstimulated myocardium. These findings are in keeping with those from previous canine studies (22, 33) suggesting that physiologically relevant concentrations of bradykinin have no direct effect on myocardial contractility in vivo. Although Munch and Longhurst (33) demonstrated positive inotropic responses (accompanied by increases in coronary blood flow) during intracoronary injections of bradykinin in open-chest dogs, these responses were eliminated when flow was first maximally increased with the vasodilator adenosine. This suggested that the initial bradykinin-induced increases in myocardial contractility were not due to a direct effect on the myocardium but secondary to Gregg's phenomenon (15) .
Recent studies (3) have shown that constitutive endothelial NOS is also expressed within the cardiomyocytes. We have no way of ascertaining whether our administrations of L-NAME blocked this potential pathway for increased tissue cGMP levels. However, because the amount of NOS in the cardiomyocytes is normally very small (compared to that in the coronary vascular endothelium), this factor should not have influenced our results substantively.
Taken together, our findings in unstimulated and inotropically stimulated myocardium, provide a compelling argument against NO as an important modulator of contractile function in the normal, in situ heart. The extensive coronary vasodilation observed during the administrations of ACh, bradykinin, and SNP, and stimulation of the vagus nerves suggests that these interventions caused significant increases in NO concentration within the coronary vascular smooth muscle. The absence of apparent NO-mediated decreases in myocardial contractility suggests a relative lack of responsiveness of the myocytes (compared to vascular smooth muscle) to NO, a restricted access of NO to the myocytes, or a combination of these factors. It is possible that myoglobin, a known scavenger of NO (23), acts as a barrier for movement of NO from the vascular endothelium to the surrounding parenchyma.
In summary, the present findings indicate that ACh has an negative inotropic effect in vivo, which requires a concurrent increase in tissue cAMP level and which is independent of NO. The increases in cAMP level need not be associated with activation of ␤-adrenergic receptors or of adenylate cyclase. Our findings add to the accumulating evidence that NO, in physiologically relevant concentrations, is not an important modulator of ventricular contractile function in vivo.
